In some countries, this medicine may only be approved for veterinary use.
CAS registry number (Chemical Abstracts Service)
A mixture of Tulatromycin A and Tulatromycin B (in equilibrium in solution) (WHO)
Tulatromycinum A:(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-metyl-3-O-metyl-4-C-[(propylamino)metyl]-α-L-ribo-hexopyranosyl)oxy]-2-etyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexametyl-11-[[3,4,6-trideoxy-3-(dimetylamino)-β-D-xylo-hexopyranosyl]o (WHO)
Tulatromycinum B:(2R,3R,6R,8R,9R,10S,11S,12R)-11-[(2,6-Dideoxy-3-C-metyl-3-O-metyl-4-C-[(propylamino)metyl]-α-L-ribo-hexopyranosyl)oxy]-2-[(1R,2R)-1,2-dihydroxy-1-metylbutyl]-8-hydroxy-3,6,8,10,12-pentametyl-9-[[3,4,6-trideoxy-3-(dimetylamino)-β-D-xylo-he (WHO)
- Tulathromycinum (Latin)
- Tulathromycin (German)
- Tulathromycine (French)
- Tulathromycina (Spanish)
- Tulathromycin (OS: USAN, JAN)
- CP-472,295 (IS: Pfizer)
- CP-547,272 (IS: Pfizer)
- Draxxin (veterinary use)
Orion Pharma Animal Health, Sweden; Pfizer, Poland; Pfizer Animal Health, Netherlands; Pfizer Animal Health, South Africa; Zoetis, Germany; Zoetis, Finland; Zoetis, France; Zoetis, United Kingdom; Zoetis, Italy; Zoetis, United States; Zoetis Australia, Australia; Zoetis Belgium, Austria; Zoetis Belgium, Belgium
- Draxxin 10% (veterinary use)
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.